Industry News — Clinical Updates

Iluvien Receives Marketing Authorization in the Netherlands for Chronic DME

The Dutch Inspectie voor de Gezondheidszorg (IGZ) has granted marketing authorization to Iluvien (sustained-release fluocinolone acetonide implant; Alimera Sciences, Inc, Atlanta, GA) for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

The IGZ approval marks the sixth European approval of Iluvien through the Repeat-Use Procedure and fourteenth approval worldwide.

Updated December 1, 2014